FDA keeps up support for generics companies

The US Food and Drug Administration (FDA) is ensuring that action follows its promises on making life easier for companies making generics to bring costs down in the USA’s health system.

Its latest step towards doing this is an update to the list identifying all drug products about which FDA has received a reference listed drug (RLD) access inquiry.

The list was created as the agency has received numerous inquiries from prospective generic drug applicants who indicate being interested in developing copies but who report being unable to obtain samples of the RLD.